Elizabeth Iorns, Ph.D., CEO of Science Exchange Elected to the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT)

November 15, 2017 | Posted by Team in News |

Elizabeth Iorns elected to DCAT Board

PALO ALTO, CA, November 15, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced today that Elizabeth Iorns, Ph.D., CEO of Science Exchange, has been elected to serve her first term on the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2017.  Members of DCAT’s Board of Directors are charged with the important work of guiding the organization’s strategic initiatives and activities.

“We are delighted to have Dr. Iorns join the Board of Directors,” said DCAT Executive Director Margaret Timony. “She brings a unique mix of leadership experiences that will add a valuable perspective to the board.”

“I am honored to join the board and work together with this great team to address key initiatives related to the pharmaceutical industry,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Our mission at Science Exchange is to help accelerate innovation and scientific discoveries, and as a scientist myself, I feel joining DCAT’s board is a perfect opportunity for me to share my ideas and insights to support and advance its programs and services.”

About DCAT

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.

 

Explore Science Exchange’s network of qualified service providers for:

 

 

Science Exchange Scientific Provider Elion Labs Presenting New Research at the AAPS Annual Meeting

November 13, 2017 | Posted by Team in Events, News |
  • Breakthrough in drug product particle analysis using machine learning

  • Biopharma researchers can access Elion’s new services from scienceexchange.com

Science Exchange and Elion at AAPS

PALO ALTO, CA, and LOUISVILLE, CO, November 13, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development, is proud to announce that Elion Labs, provider of analytical development and drug product characterization services, will present exciting new research at the 2017 AAPS (American Association of Pharmaceutical Scientists) Annual Meeting, the most comprehensive event for innovations in bioanalysis, formulation, and product characterization.

Elion’s expertise has helped bring numerous clinical products to market. Their AAPS research poster presentation (Abstract M8003) introduces a novel method for drug product analysis, using machine learning and advanced image analysis to improve particle detection, enumeration, and classification.

“Machine learning approaches open up exciting new possibilities for analyzing particles in biologics, and ultimately, for better analyzing a broad range of complex data sets,”  said John Gabrielson, Ph.D., CEO and Founding Partner of Elion Labs. “We hope that our research will help biopharmaceutical researchers develop safer, more effective drugs and deliver them to patients faster.”

Elion and Science Exchange will exhibit at booth 2337 at AAPS, meeting drug discovery and development researchers and representatives of regulatory agencies seeking the latest, innovative services available for pharmaceutical analysis.

“We’re proud to participate in this year’s conference alongside Elion, who are true thought leaders in analytical research,” said Elizabeth Iorns, Ph.D., CEO and Co-Founder of Science Exchange. “And because they’re part of the Science Exchange network, biopharmaceutical researchers can access Elion’s technologies immediately under our pre-existing master service agreement that covers IP and confidentiality.”

More information about Elion Labs and their innovative services can be found at www.scienceexchange.com/labs/elion-labs.

 

About Elion Labs

Elion Labs, based in Louisville, Colorado, USA, was founded to serve the analytical development and product characterization needs of the biopharmaceutical industry. Elion offers a variety of services, including analytical method development, qualification and validation; analytical characterization testing of biologics; formulation development; training in highly specialized analytical techniques; comprehensive data analysis including visualization and interpretation of complex data sets; technical and regulatory writing; and technical consulting. They are committed to providing all services with unmatched professionalism, quality, and speed.

About Science Exchange

Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

 

 

Science Exchange Announces New Director of Scientific Content, Gursatya “Guru” Singh

November 2, 2017 | Posted by Team in News |

Guru Singh Science Exchange

PALO ALTO, CA, November 2, 2017Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that Gursatya “Guru” Singh has joined the company’s management team as Director of Scientific Content.

“Adding Guru to our team is part of our ongoing commitment to strengthen the management team with industry experts who are dedicated to disrupting the traditional R&D outsourcing model,” said Elizabeth Iorns, Ph.D., CEO and co-founder of Science Exchange. “Guru’s experience in this industry will help us better inform the scientific community about the benefits of accessing innovation through the Science Exchange platform.”

Singh’s background includes experience as a laboratory researcher and entrepreneur, as he has helped launch several life science startups. This included a previous role where he developed scientific content to promote the innovative services and technologies of scientific service providers. Singh also has published several scientific papers.

A frequent blogger and thought leader in pharma and biotech outsourcing, Singh founded a Facebook group – Mysteries of Biotech – that has amassed nearly 5,000 followers. He holds a master’s degree in biotechnology from the University of Delaware and a bachelor’s degree in biotechnology from Sharda University in India.

“I am excited to join Science Exchange — the most trusted outsourcing platform for scientific products and services,” said Singh. “Science Exchange is a trailblazing company that is revolutionizing R&D outsourcing by helping companies around the world bring their innovations to market faster. I can’t think of a better place to be.”

Elizabeth Iorns, Ph.D., Named 2017 Scrip Award Executive of the Year Finalist

November 1, 2017 | Posted by Team in News |

Scrip Award Finalist Elizabeth Iorns

PALO ALTO CA, November 1, 2017 –  Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that company CEO and co-founder Elizabeth Iorns, Ph.D., has been selected as an Executive of the Year finalist in the prestigious 2017 Scrip Awards.

Dr. Iorns is one of six C-level executives recognized in the Executive of the Year category for private companies or those with a market capitalization of <$1 billion. This awards category acknowledges excellence in the leadership of large and small pharmaceutical and biotechnology companies around the world.

A cancer researcher herself, Iorns co-founded Science Exchange in 2011 to streamline R&D outsourcing and facilitate access to qualified, innovative scientific service providers. Because of the robust platform’s clear benefits to R&D organizations, she has successfully negotiated enterprise-level agreements between Science Exchange and many of the world’s top biopharma companies, as well as with numerous biotech and pharma startup incubators. Over the past year, in addition to expanding the company’s reach into other R&D reliant industries like agrisciences and cosmetics, Iorns led the a successful Series C venture capital funding round, bringing an additional $28 million of investment that will allow Science Exchange to accelerate its impressive growth.

Iorns is also the co-director of the Reproducibility Initiative, and is a part-time partner at Y Combinator. She has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK), and before starting Science Exchange was an Assistant Professor at the University of Miami, where she remains an Adjunct Professor. She has been recognized previously as one of Nature’s “Ten People that Mattered” and WIRED’s “50 Women Who Are Changing The World.”

In its 13th year, the Scrip Awards program recognizes the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. A panel of 16 highly respected and independent experts from across diverse sectors evaluated the award entries to select the finalists. The winners across 16 categories will be announced at the 13th Annual Scrip Awards ceremony at the London Hilton on Park Lane in London, England on November 29, 2017. For more details on the event, visit www.ScripAwards.com.  

New on Science Exchange: VR Tech, Cancer Genetics, Stem Cell-based Organoids

October 26, 2017 | Posted by Team in Innovation Highlight, New Innovations |

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com

Nanome Virtual Reality

Virtual Reality Software: Explore biology at nanoscale

From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain technology, makes such journeys possible.

For your next computer-aided drug discovery/development (CADD) project, especially if you are collaborating with researchers across multiple sites, try molecular visualization using VR technology — now available from Nanome through Science Exchange.

Visit the Nanome storefront to connect with their team!

 

Cancer Genetics: Connect patients to discoveries

It’s a great day for precision medicine, with the unveiling of the first global directory of patient-derived xenografts (PDX).

Despite the attention given to precision medicine, however, less than 5% of cancer patients are participating in clinical trials. In the discovery phases of R&D, obtaining biospecimens of specific genotypes is also a continuing challenge.

Oncologists on Science Exchange can now accelerate their research with Cancer Genetics, Inc., a global CRO with a history of thought leadership in precision medicine.

Start a project today with Cancer Genetics, Inc.

 

Stem Cell-based 3D Organoids: Predict Preclinical Efficacy and Toxicity

3Dnamics Organoid Hippocampus

Organoids, particularly brain organoids, have enabled breakthrough research in Alzheimer’s disease, glioblastoma, and even ZIKA virus-induced microcephaly. By using pluripotent stem cells as a source of the multiple cell types present in an organoid, preclinical researchers can recapitulate in vivo-like tissue architecture and cellular heterogeneity.

Many of these discoveries were made by the founders of 3Dnamics, a new service provider on the Science Exchange network. The 3Dnamics team was built by stem cell pioneers and neuroscientists at Johns Hopkins University School of Medicine. If you are in the process of developing a model system for your preclinical or discovery-phase research, take advantage of 3Dnamics’ expertise.

Visit the 3Dnamics storefront

 

Accelerating Innovation and Mitigating Risk in Outsourced R&D

October 25, 2017 | Posted by Team in Outsourcing Trends |

Science Exchange Summit 2017

by Elizabeth Iorns, Ph.D., CEO and Co-Founder, Science Exchange | www.scienceexchange.com

Science Exchange recently hosted a group of procurement executives from multiple industries for our 2017 Science Exchange Outsourced R&D Leadership Summit. During the informative and interactive sessions, we discussed both the challenges and opportunities that organizations are facing as they seek to effectively manage outsourced R&D services.

From presentations by procurement leaders from major pharmaceutical companies on how they’re structuring procurement to enable innovation, to insights on how Science Exchange is pioneering new ways to make it easier to access innovation from our service providers, one of the key themes of the day was the potential for the procurement function to empower scientists to achieve breakthrough discovery. Here are some of my notes around the theme of innovation:

  • Procurement leaders can drive innovation, with the right tools. A pharmaceutical company procurement leader responsible for driving innovation shared that, in less than six months of working with Science Exchange, they had been able to increase their use of new, niche service providers by 11%.
  • Innovation can be hampered by complex processes. Natalie Foote, our Director of Service Provider Operations, presented with two of our service providers — iSpecimen and LabNetwork, a WuXi AppTec company– about new technology integrations with our platform. These integrations allow Science Exchange users to access the iSpecimen and LabNetwork marketplaces through a seamless access point on our platform — no barriers to innovation!
  • Flexible, agile procurement support helps drive innovation. During a panel discussion that I moderated, procurement leaders from three global pharmaceutical companies examined the need to more flexible and agile when it comes to managing R&D requests, and supporting the R&D business through an end-to-end process. They also discussed how their organizations must strategically examine the best mix of internal and external capabilities, core strengths and capacity when it comes to maximizing R&D innovation.

Another theme that surfaced during the Summit was risk mitigation, including the need to better manage confidentiality, data security and intellectual property (IP), and how to prepare for business continuity — whether caused by security breaches or natural disasters. My notes on the theme of risk mitigation:

  • Proactively mitigate risk. During the panel discussion, procurement leaders talked about the need to move beyond a “paper exercise” for managing risk, to a more proactive and rigorous approach to protecting their companies from data and security breaches and business continuity issues. One panelist discussed the drive for holding the business accountable for third-party risk oversight on a global scale, to move beyond that “check the box” mentality.   
  • Balance risk and innovation opportunity. Another panelist emphasized how important it is to strike the delicate balance between managing risk and enabling innovation, to ensure that businesses are protected without slowing down or blocking important scientific discoveries.  
  • Ask the right questions to assess risk. Our Director of Contracts & Compliance, Andrew Gutierrez, highlighted the need to ask the right questions in developing contracts and programs that will protect a company’s confidentiality and IP.He also talked about the need to verify how your data is being protected by your partners to ensure compliance with global regulations.

The Science Exchange Summit gave our entire team an opportunity to deepen our understanding of the needs of global procurement leaders, and our attendees gained insights to bring back to their own organizations, and a network of experts to collaborate with in the future. I look forward to continuing these discussions with our customers so we can continue to learn from one another and accelerate scientific discovery!

Learn more about how Science Exchange can help you — request a demo today.

iSpecimen and Science Exchange Announce Technology Integration to Allow Instant Access to Human Biospecimens

October 24, 2017 | Posted by Team in News |

Scientists in search of human biospecimens can now search the iSpecimen Marketplace via Science Exchange as part of one seamless experience

LEXINGTON, Mass. and PALO ALTO, Calif.Oct. 24, 2017 /PRNewswire/ —iSpecimen and Science Exchange today announced a marketplace technology integration that will allow Science Exchange users to directly search for biospecimens available in the iSpecimen Marketplace via a single user interface.

Science Exchange is the world’s leading and most secure platform for outsourced research and development (R&D) services, and the iSpecimen Marketplace is the premier online platform instantly connecting life science researchers in need of human biospecimens with the healthcare organizations that have them. By integrating these two solutions, Science Exchange users will now have access in real time to more than 25 million banked and prospectively collected specimens, including biofluids, solid tissue, and cells, all available on the iSpecimen Marketplace.

“iSpecimen shares our commitment to accelerating breakthrough scientific discovery through innovative technology,” said Elizabeth Iorns, PhD, Founder and CEO, Science Exchange. “With the seamless integration of the iSpecimen Marketplace and Science Exchange platform, our users gain direct, on-demand access to millions of human biospecimens.”

While iSpecimen has been available through Science Exchange since 2014, the new integration minimizes the time and complexity involved with specimen procurement. Additionally, the legal and compliance infrastructure in place for Science Exchange users reduces the risks often associated with biospecimen procurement. In the iSpecimen Marketplace, researchers have instant access to compliance documentation on a per specimen basis, giving researchers assurance before obtaining specimens that their requested samples were ethically sourced with appropriate regulatory oversight.

“The drive towards precision medicine is advancing the pace of research and increasing the need for biospecimens and related services,” said Christopher Ianelli, MD, PhD, Founder and CEO, iSpecimen. “The integration of the iSpecimen Marketplace into the Science Exchange environment accelerates research by giving scientists broader access to specimens from within the world’s leading platform for outsourced scientific services. We are honored to be working with Science Exchange in this way.”

Researchers interested in iSpecimen and Science Exchange can learn more and see demonstrations this week at ProcureCon Pharma in Philadelphia, where both Ianelli and Iorns will be speaking as part of a plenary panel.

QB3 Signs Partnership with Science Exchange

October 23, 2017 | Posted by Team in News |

Qb3 Partners With Science ExchangeBay Area Life Science Hub Enables its Startups to Stay Lean with Science Exchange’s R&D Platform

PALO ALTO, CA, October 23, 2017Science Exchange, a platform for outsourced research and development (R&D) services, today announced a partnership with QB3, the University of California hub for innovation and entrepreneurship for life sciences.

Through an exclusive Science Exchange-QB3 marketplace, QB3-affiliated companies will now have access to a customized and secure marketplace where they can instantly order R&D services from a network of more than 2,500 qualified scientific service providers. Science Exchange’s scientific concierge staff also will offer support to QB3’s start-up companies in identifying innovative providers and ordering complex R&D services.

“Science Exchange will help accelerate our companies by giving them access to providers that are experienced with entrepreneurial research and that have already been reviewed and qualified,” said Ioana Aanei, Ph.D., Entrepreneurship Program Manager at QB3. “Many of our startups don’t have the resources to purchase their own capital equipment or do the necessary specialized scientific research in-house.”

“Science Exchange is committed to helping life science companies bring innovative, potentially life-saving products to market,” said Elizabeth Iorns, Ph.D., Founder & CEO of Science Exchange. “While QB3’s companies focus on discovery, we can help eliminate the barriers, including the time and expertise needed to research and qualify contract research organizations (CROs) and scientific service providers. We also help save time and money in contract negotiation, all while ensuring the protection of intellectual property.”

QB3 joins more than 30 enterprise clients and entrepreneurial incubators that are efficiently managing their outsourced R&D with Science Exchange-powered marketplaces.

About QB3

QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The institute supports UC researchers and empowers Bay Area entrepreneurs to launch startup companies and partner with industry. QB3 helps bio-entrepreneurs create hundreds of high-value jobs and bring more than $750 million into the Bay Area each year. With campus divisions at Berkeley, San Francisco, and Santa Cruz, QB3 is also affiliated with the San Francisco incubator [email protected] — home to more than 45 companies — and the seed-stage venture capital firm Mission Bay Capital. Visit us at http://qb3.org/.

 

Science Exchange Honored by Goldman Sachs for Entrepreneurship

October 19, 2017 | Posted by Team in News |

Co-Founder and CEO Elizabeth Iorns Among 100 Most Intriguing Entrepreneurs at 2017 Builders + Innovators Summit

Palo Alto, CA – October 19, 2017 – Goldman Sachs (NYSE:GS) is recognizing Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange as one of the 100 Most Intriguing Entrepreneurs of 2017 at its Builders + Innovators Summit in Santa Barbara, California.

Goldman Sachs selected Elizabeth as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.

The life sciences research community has been transformed by Elizabeth’s ability to execute upon her vision to transform the procurement and delivery of outsourced R&D services. Thanks to her tenacity and drive, and her deep understanding of the need for improved R&D efficiency, Science Exchange is enabling breakthrough scientific discoveries by providing researchers with an online platform for efficient access to the world’s best outsourced R&D service providers.

“This is a tremendous honor and I’m excited to be recognized by Goldman Sachs along with these other inspiring entrepreneurs,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “The work our team at Science Exchange has been doing in outsourced R&D is critical for driving scientific breakthroughs and innovation and I’m proud to lead the team in this charge.”

“We are pleased to recognize Elizabeth Iorns as one of the most intriguing entrepreneurs of 2017,” said David M. Solomon, President and Co-Chief Operating Officer at Goldman Sachs. “This is the sixth year that we’ve hosted the Builders + Innovators Summit where emerging business leaders gather to discuss their common interests in building prosperous organizations.”

For more than 145 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the Summit consists of general sessions and clinics led by Goldman Sachs experts, seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Elizabeth Iorns

Elizabeth Iorns, Ph.D., is the CEO and Founder of Science Exchange. Elizabeth Iorns has transformed scientific research by radically improving the procurement and delivery of outsourced research and development (R&D) services. Elizabeth Iorns, Ph.D. (Institute of Cancer Research, London) was an Assistant Professor at University of Miami’s Miller School of Medicine, where she investigated breast cancer development and progression, before launching Science Exchange in 2011. Elizabeth’s work has been featured in multiple media outlets, and she regularly speaks at thought leadership events, such as the 2017 TechCrunch Disrupt event in San Francisco, 2017 Society for Laboratory Automation and Screening annual meeting and the 2016 MassBio CRO/CMO Symposium. Her recent honors include Nature’s “Ten People that Mattered,” WIRED’s “50 Women Who Are Changing The World,” and the “Kauffman Foundation Emerging Entrepreneur Award.” She is a finalist for 2017 Scrip Executive of the Year Award.

About Science Exchange
Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

Service Provider Qualification and Monitoring Processes at Science Exchange

October 9, 2017 | Posted by Team in Outsourcing Trends |

R&D organizations are rightfully cautious when selecting service providers. So much is at stake — reputation, intellectual property, pipeline decisions, regulatory approval, financial investments, and time. ISO 9001 Certified QMS Science Exchange

By partnering with Science Exchange, R&D organizations can finally rest assured that they are accessing a network of service providers that meets their most stringent criteria for quality and integrity.

Put your reputation into the best hands.

Every service provider on the Science Exchange platform is rigorously qualified and operates under pre-established legal agreements that protect intellectual property (IP), define confidentiality obligations, and ensure quality and compliance.

We stand by the unmatched quality of our ISO 9001-certified service provider qualification and monitoring processes. Our process verifies details of service provider compliance, reputation, financial standing, and staff expertise:

Provider Qualification & Monitoring Criteria  

Compliance Reputation Financials Expertise & Resources
  • Basic info (contact, billing, shipping)
  • Proof of certifications
  • FDA warning letters
  • USDA violations
  • Anti-bribery/Anti-corruption*
  • Social media
  • Client referrals
  • BBB complaints
  • Website verification
  • Facility/operations photos
  • Tax documents
  • Financial standing
  • Risk assessment
  • Employee headcount
  • Staff bios
  • Instrumentation
  • Detailed service descriptions
  • Validation data
  • Publications/patents

We require submission of compliance and capabilities information to help our clients determine whether the provider is the best fit for a proposed study. Information is either incorporated into the Science Exchange storefront for each facility or is stored within Science Exchange’s database. *Science Exchange checks against FPAC enforcement actions for anti-bribery/anti-corruption compliance.

Request a demo to see how our service provider quality management system protects our partner R&D organizations.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com